Sponsored/General Research projects that will implement and assess the impact of therapy management approaches for patients with HER2+ Metastatic Breast Cancer (mBC) receiving tucatinib in combination with trastuzumab and capecitabine.
Project Types and Area of Interest
Organizations are invited to submit proposals for initiatives that will implement innovative and community-accessible approaches to improving therapy management with the 3-drug regimen of tucatinib, trastuzumab and capecitabine, including increasing patients’ understanding, quality of life, or adherence to treatment and/or facilitate follow-up or symptom management in daily clinical practice.
Projects should be aimed at improving patient care and outcomes using a research framework or “Health Services Research” type approach to evaluate and assess the impact of the interventions.
Key Milestones
• Application submission deadline: Thursday, January 30, 2025
• Anticipated Notification Date: Monday, March 17, 202
Funding Range and Project Length
• Individual projects requesting up to $250,000 will be considered.
• 18-month suggested project length (may be shorter or longer)
Expires on January 31, 2025
Més posts de Concursos
Cap comentari:
Publica un comentari a l'entrada